

---

**CESSATION OF QUARTERLY REPORTING AND CHANGE TO SEMI-ANNUAL  
REPORTING OF FINANCIAL RESULTS**

---

The Board of Directors ("**Board**") of OUE Lippo Healthcare Limited ("**Company**") and together with its subsidiaries, the "**Group**") wishes to inform the shareholders of the Company that following the recent amendments to Rule 705 of the Singapore Exchange Securities Trading Limited Listing Manual Section B: Rules of Catalyst ("**Catalist Rules**") which came into effect on 7 February 2020 (the "**Amended Catalist Rules**"), the Company is no longer required to release its financial statements on a quarterly basis.

The Board has, after due deliberation (including taking into consideration the compliance costs and efforts required in connection with quarterly reporting), decided not to continue with quarterly reporting of the Company's financial statements. Instead, the Company will announce the financial statements of the Company on a semi-annual basis with effect from the financial year ending 31 December 2020 ("**FY2020**") pursuant to the Amended Catalist Rules. In view of the foregoing, for FY2020, the Company's next financial results release will be in respect of the half year period ending 30 June 2020, which will be announced via the SGXNet on or before 14 August 2020.

The Company will continue to keep shareholders updated on material developments relating to the Company or the Group, as and when appropriate, in accordance with requirements of the Catalist Rules.

By Order of the Board  
**OUE Lippo Healthcare Limited**

Mr. Yet Kum Meng  
Chief Executive Officer and Executive Director  
6 May 2020

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalyst.*

*This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg)).*

**OUE Lippo Healthcare Limited**  
Company Registration No. 201304341E  
(In receivership over charged shares in certain subsidiaries)  
6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809  
T: +65 6578 9188 F: 64794647 [www.ouelh.com](http://www.ouelh.com)